Somatostatin Receptor-Based Molecular Imaging and Therapy for Neuroendocrine Tumors

Table 3

The radioagent used in PRRT and the efficacy of the therapy.

Therapeutic agents	Subjects	Dosage	Duration	Main findings	References
^90Y-DOTATATE	46 NETs	7.4 GBq/m^2	3–5 cycles	PFS 37.4 months	[59]
^90Y-DOTATOC	116 Metastatic NETs	162–200 mCi/m^2	2–4 cycles	Significant reduction of symptoms was found in 83% of patients	[58]
^177Lu-DOTATATE	310GEP-NETs	750 to 800 mCi	4 cycles	Survival benefit of 40 to 72 months from diagnosis	[60]
^177Lu-DOTATOC	27 relapse NETs	7,400 MBq	Once	2 PR, 5 MR, 12 SD, and 8 PD	[62]